MicroPort Orthopedics Optimizing its Episode of Care for Surgeons and Patients, Investing In New Technologies and Partnerships

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

MicroPort Orthopedics, a global leader in orthopedic devices and technologies, is taking an Episode of Care approach to enhance operational efficiency and patient satisfaction throughout the 90 days both before and after surgery.

MicroPort is investing in new strategic technologies and partnerships with the vision to improve efficiencies, patient outcomes, and provider productivity.
Technologies built specifically around streamlining the Episode of Care ensure patients are prepared mentally and physically for their procedure and have digital resources to communicate with their doctors throughout the recovery process. Additionally, the resources can help healthcare providers monitor patients, predict risk, and manage outcomes.
To increase patient engagement and systematically measure patient outcomes, MicroPort recently partnered with PatientIQ, a platform that combines industry-leading patient engagement technology with research quality advanced analytics.
Together, PatientIQ and MicroPort Orthopedics are guiding the future of orthopedic care. With over 1,600 online education modules, PatientIQ provides a top-tier patient experience that can be specifically tailored to a procedure or a diagnosis. In addition to preoperatively educating and optimizing patients for their upcoming surgery, the platform also administers patient outcomes surveys and automates data collection throughout the entire Episode of Care to provide full service and support to both patients and surgeons.
MicroPort Orthopedics has also recently partnered with Dr. Aaron Salyapongse, orthopaedic surgeon in Dublin, California, to develop a Virtual Joint Class series moving patient education content to a digital format, allowing them to prepare for their upcoming surgery.
These classes, available through MicroPort’s proprietary PATHWAYS program, are specifically designed in a relatable and interactive blackboard style format to keep patients interested and engaged. They provide details about what to expect during and after the procedure. The classes not only introduce a breadth of topics including surgical preparation, anesthesia, discharge criteria, and post-op pain management, but also preemptively address many of the common causes for patient adverse events and readmissions.”
“Over the last 20 years, total joint replacement surgery has undergone a significant evolution. In the early 2000s, it was common for patients to spend days in a hospital for a procedure and then be moved to a skilled nursing facility for several weeks. Today, patients are routinely discharged hours after the procedure without any added risk and at a lower cost compared to a traditional inpatient setting,” said Benny Hagag, president of MicroPort Orthopedics.
Hagag concluded, “These systemic changes to the Episode of Care, combined with the impact of COVID-19 on today’s healthcare system, have required companies to adapt and prioritize innovation and technology at the center of care. Our recent collaboration and strategic partnerships with like-minded companies and surgeons are what keep us advancing toward positive patient outcomes and effective procedures, and we are only getting started.”


Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles